Skip to content

Measurement of Gastric Emptying During and After COLOKIT® Intake

Gastric Emptying Time Assessment During Bowel Preparation With COLOKIT®

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01398098
Enrollment
30
Registered
2011-07-20
Start date
2011-10-31
Completion date
2012-09-30
Last updated
2012-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonoscopy

Brief summary

Ultra-sound study to assess changes in intragastric volume after bowel preparation.

Interventions

32 tablets

Sponsors

Laboratoires Mayoly Spindler
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Subject who signed an informed consent to participate in the trial. * Subject affiliated with Social Security * Men and women aged 18 to 75 years. * Subject with an indication of scheduled outpatient colonoscopy. * colonoscopy performed within six hours after the second sequence COLOKIT®. * Subject able to swallow tablets.

Exclusion criteria

1. Women pregnant or likely to be (without contraception) or nursing. 2. Subject having any of the following diseases or conditions: * allergy or hypersensitivity to the product tested or any of its excipients, * nausea, vomiting or abdominal pain, * clinically significant renal failure, * primary hyperparathyroidism associated with hypercalcemia, * congestive heart failure, * ascites, * a known or suspected bowel obstruction, * megacolon (congenital or acquired) * intestinal perforation, * ileus, * an inflammatory disease or suspected inflammatory bowel disease, * swallowing disorders, * known digestive motor disorders (gastroparesis, scleroderma, mega-esophagus), * diabetes mellitus (insulin or non insulin-dependent) * a history of gastric surgery (partial or total) * a contraindication to the anesthesia required for the completion of the colonoscopy, * Any clinical condition which, in the opinion of the investigator, would not allow the subject to perform the test in good conditions.

Design outcomes

Primary

MeasureTime frame
Percentage of patients with a residual antral volume lower than 20 mLafter 2nd treatment regimen intake

Secondary

MeasureTime frame
Adverse eventsAfter drug intake
Acceptability of COLOKIT®.After drug intake
Colonoscopy resultsAfter colonoscopy.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026